As expected, HCC in the low risk score group had lower IC50 values for axitinib, cisplatin, dabrafenib, gemcitabine, KRAS inhibitor, oxaliplatin, selumetinib, and sorafenib (Fig. 5F). The gene discussed is KRAS; the disease is hepatocellular carcinoma.